Anticholinergics Flashcards

1
Q

What kind of drug are anticholinergics?

A

competitive antagonists
-competitive and reversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ACh neurotransmission: M antagonists

A

ACh binds to cholinoceptors on the postsynaptic cell
-M receptor antagonists (antimuscarinics)
-agents are competitive antagonists for M receptors (M1, M2, M3): smooth muscle, cardiac muscle, exocrine glands

atropine: oldest and most well known antimuscarinic agent that’s an antagonist at M1, M2, and M3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

atropine

A

general considerations: muscarinic receptor blockade
-competitive antagonism at the M receptor (M1, M2, M3)-mediated actions of ACh on autonomic effectors innervated by postganglionic cholinergic nerves, as well as smooth muscles

ganglia: little effect on ACh binding to nicotinic receptor

CNS: widespread distribution of muscarinic receptors throughout brain
-therapeutic doses are attributable to central muscarinic blockade
-atropine can produce partial block (M1) only at relatively high doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

effects of atropine

A

low to high dose: exocrine glands, eye, CVS, respiratory tract, urinary bladder, GI smooth muscle, CNS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

antimuscarinics: general chemical properties

A

mechanism: competitive and reversible inhibition of M receptor activation by preventing the binding of ACh

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

classes of antimuscarinics

A

tertiary amines: mainly used in ocular and CNS applications
-no charge: can cross BBB
-ex. atropine
quaternary amines: mainly used in GI tract and peripheral applications
-positive charge: can’t cross BBB
-ex. anisotropine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

muscarinic antagonists: tertiary amine examples

A

belladonna alkaloids (long lasting)
-atropine
-scopolamine
tertiary amine derivatives (short acting)
-homatropine
-tropicamide
tertiary amine derivatives (antiparkinson use)
-benztropine
-trihexyphenidyl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

muscarinic antagonists: quaternary amine examples

A

derivatives of belladonna alkaloids
-ipratropium
-tiptropium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

long lasting tertiary amines

A

atropine and scopolamine
-M1/M2/M3 nonselective
-treat GI/urinary conditions, motion sickness
-tertiary compounds can affect CNS
–scopolamine has higher penetration, induces greater drowsiness (low doses) or hallucinations (high doses)
-naturally occuring
–belladonna from Italy, used to dilate eyes
–deadly nightshade
–historically used as hallucinogen: confusion, dilated pupils, tachycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

scopolamine

A

action: antimuscarinic with relatively more CNS action than atropine (highly lipophilic)
-has an extra O on it
clinical use: effective Tx of motion sickness (oral, transdermal administration)
SE: dry mouth, blurred vision, sedation
-high doses: confusion, psychosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

short acting tertiary amines

A

homatropine, tropicamide
-used in optical applications due to short duration of action
-cycloplegia and mydriasis
homatropine is less toxic, tropicamide has shorter duration of action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

tertiary amines for Parkinson’s Disease

A

benztropine
-sedative activity
-used as adjunct therapy with L-DOPA in PD patients (achieve better balance between dopaminergic and cholinergic neurotransmission)
-similar potency to atropine (less SE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

quaternary amines for COPD

A

ipratropium
-action: antimuscarinic with receptor activity similar to atropine, M3 antagonist blocks ACh-mediated constriction and open the airways
-clinical use: Tx of COPD, occasionally asthma
–less effective as monotherapy but enhances therapeutic effect of b-adrenergic agonists in COPD
–combivent or duoneb: combination of ipratropium and albuterol in treating COPD
-problems: few because of poor absorption, toxic doses can cause hypotension (ganglionic blockade), muscle weakness (neuromuscular blockade)

triotropium: longer acting analog

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

quaternary amines for GI disorders

A

glycopyrrolate, propantheline bromide
-used to treat gastric disorders (GI spasms, peptic ulcers)
-glycopyrrolate: pre-op to reduce secretions, charged N makes crossing the gut difficult = fewer SE
-propantheline bromide isn’t available in the US

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

antimuscarinics for overactive bladder

A

tolterodine
-action: no apparent selectivity for different M receptor subtypes, therapeutically seems to act somewhat selectively on M3
-clinical use: OAB
-problems: still causes typical anticholinergic effects, but significantly lower than with previous antimuscarinic drugs

newer M3-selective muscarinic antagonists to treat OAB
-solifenacin, darifenacin, oxybutynin
-proposed advantages: lower incidence of constipation and confusion

b3 receptor agonist: mirabegron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

antimuscarinic poisoning

A

over 600 meds prescribed and OTC have drugs with antimuscarinic properties
-H1 receptor antagonists (diphenhydramine)
-older antipsychotics (chlorpromazine)
-tricyclic antidepressants (amitriptyline)
often see antimuscarinic effects at therapeutic dose (ex. dry mouth)
Tx: change med/decrease dose, supportive care (sodium bicarb for prolonged QRS or arrhythmias, benzodiazepines for agitation/delirium), physostigmine (acetylcholinesterase inhibitor)
identify potentially inappropriate meds for elderly
-est. 30-60% of nursing home residents receive meds with signigicant antimuscarinic effects
-Beers Criteria
-STOPP (screening tool of older persons’ potentially inappropriate prescriptions)

17
Q

nicotinic receptor antagonists

A

Na+ channel receptor

18
Q

effects of nicotine on muscle: stimulation

A

normal operation of nicotinic receptors is the rapid degradation of synaptically released ACh
-allows neuronal membrane/muscle endplate to repolarize and fast Na+ channels (responsible AP) to reset
-next ACh release causes another depolarization that triggers opening of rested Na+ channels and AP
–use AChE to block

19
Q

effects of nicotine on muscle: desensitization

A

nicotinic receptors are specifically adapted to transient nature of ACh as a neurotransmitter
-agonist remains bound to receptor: persistent depolarization means fast Na+ channels can’t reset to active state

20
Q

blocking the nicotinic receptor

A

non-depolarizing blockade (normal antagonist): tubocurarine
depolarizing blockade (first activates then blocks): succinylcholine
neuromuscular blocking agents look like ACh

21
Q

tubocurarine

A

action: nicotinic receptor competitive antagonist producing non-depolarizing blockade
clinical use: skeletal muscle relaxation during anesthesia, particularly useful for intubation
problems: minor

22
Q

succinylcholine

A

mechanism of action: binds to nicotinic ACh receptor
-agonist nicotinic receptor, initial depolarization
-persistent depolarization makes muscle fiber resistant to further stimulation by ACh (prevents resetting of voltage-gated Na+ channels)
-metabolized to choline by plasma butyrylcholinesterase
–slower than AChE, choline increases BP, muscle fasciculation precedes paralysis, arm, neck, leg then respiratory muscles, rapid onset, short duration

clinical use: skeletal muscle relaxation during anesthesia, particularly useful for intubation, electro-convulsant therapy

problems: muscle soreness (avoid in hyperkalemia, cause of cardiac arrest), malignant hyperthermia, prolonged paralysis can result in people with atypical plasma cholinesterases

23
Q

hexamethonium

A

action: antagonist at nicotinic receptors in autonomic ganglia thus blocking all SNS and PSNS activity
use: originally for hypertension, not used clinically due to adverse effects
problems
-blood vessels (SNS): hypotension
-sweat glands (SNS): decreased perspiration
-other glands (PSNS): dry mouth, decreased secretions
-heart rate (PSNS): tachycardia (if SNS is active you’ll see bradycardia)
-eye (PSNS): pupillary dilation, blurred vision
-gut (PSNS): decreased tone and motility, constipation
-bladder (PSNS): urinary retention

24
Q

inhibition of ACh release: botulinum toxin

A

action: inhibit release of ACh
clinical use: dystonias (uncontrolled muscle spasms), cerebral palsy, spasm of ocular muscles, anal fissure, hyperhidrosis (excessive sweating)
problems: spread form injection site